These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28183082)

  • 1. Why Current PTH Assays Mislead Clinical Decision Making in Patients with Secondary Hyperparathyroidism.
    Hocher B; Yin L
    Nephron; 2017; 136(2):137-142. PubMed ID: 28183082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between GFR, intact PTH, oxidized PTH, non-oxidized PTH as well as FGF23 in patients with CKD.
    Zeng S; Querfeld U; Feger M; Haffner D; Hasan AA; Chu C; Slowinski T; Bernd Dschietzig T; Schäfer F; Xiong Y; Zhang B; Rausch S; Horvathova K; Lang F; Karl Krämer B; Föller M; Hocher B
    FASEB J; 2020 Nov; 34(11):15269-15281. PubMed ID: 32964520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients.
    Zuo J; Hasan AA; Hocher CF; Kalk P; Kleuser B; Krämer BK; Hocher B
    Front Endocrinol (Lausanne); 2023; 14():1178166. PubMed ID: 37324252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of oxidized PTH (oxPTH) and non-oxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients.
    Hocher B; Oberthür D; Slowinski T; Querfeld U; Schaefer F; Doyon A; Tepel M; Roth HJ; Grön HJ; Reichetzeder C; Betzel C; Armbruster FP
    Kidney Blood Press Res; 2013; 37(4-5):240-51. PubMed ID: 23868100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-oxidized PTH (n-oxPTH) is associated with graft loss in kidney transplant recipients.
    Lu YP; Zeng S; Chu C; Hasan AA; Slowinski T; Yin LH; Krämer BK; Hocher B
    Clin Chim Acta; 2020 Sep; 508():92-97. PubMed ID: 32413401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients.
    Tepel M; Armbruster FP; Grön HJ; Scholze A; Reichetzeder C; Roth HJ; Hocher B
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4744-51. PubMed ID: 24171919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Only bioactive forms of PTH (n-oxPTH and Met18(ox)-PTH) inhibit synthesis of sclerostin - evidence from in vitro and human studies.
    Li M; Hasan AA; Chu C; Hocher JG; Liu Y; Zhang X; Chen X; Yard B; Krämer BK; Hocher B
    Pflugers Arch; 2024 Jun; 476(6):889-899. PubMed ID: 38393416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological Activity of Different Forms of Oxidized Parathyroid Hormone.
    Hasan AA; Hocher CF; Kleuser B; Krämer BK; Hocher B
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low parathyroid hormone levels after parathyroidectomy reduce cardiovascular mortality in chronic hemodialysis patients.
    Iwamoto N; Sato N; Nishida M; Hashimoto T; Kobayashi H; Yamazaki S; Okino K; Nishimura M; Takatani T; Okamoto Y; Nakanouchi T; Koyama M; Adachi N; Ninomiya K; Mabuchi H; Iseki K
    Clin Exp Nephrol; 2016 Oct; 20(5):808-814. PubMed ID: 26677857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidation of PTH: in vivo feature or effect of preanalytical conditions?
    Ursem SR; Vervloet MG; Hillebrand JJG; de Jongh RT; Heijboer AC
    Clin Chem Lab Med; 2018 Jan; 56(2):249-255. PubMed ID: 28809747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between total mass and blood supply of parathyroid glands and their secretion of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
    Ahmadi F; Aghajanzadeh P; Yazdi HR; Maziar S; Gatmiri SM
    Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):263-9. PubMed ID: 26997379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between whole and intact parathyroid hormone assays.
    Taniguchi M; Tanaka M; Hamano T; Nakanishi S; Fujii H; Kato H; Koiwa F; Ando R; Kimata N; Akiba T; Kono T; Yokoyama K; Shigematsu T; Kakuta T; Kazama JJ; Tominaga Y; Fukagawa M
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():42-9. PubMed ID: 21595852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential changes in plasma intact and whole parathyroid hormone levels during parathyroidectomy for secondary hyperparathyroidism.
    Yamashita H; Cantor T; Uchino S; Watanabe S; Ogawa T; Moriyama T; Takamatsu Y; Fukagawa M; Noguchi S
    World J Surg; 2005 Feb; 29(2):169-73. PubMed ID: 15650804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.
    Geng S; Kuang Z; Peissig PL; Page D; Maursetter L; Hansen KE
    Osteoporos Int; 2019 Oct; 30(10):2019-2025. PubMed ID: 31190122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
    Salam SN; Khwaja A; Wilkie ME
    Drugs; 2016 May; 76(8):841-52. PubMed ID: 27142279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
    Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
    Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel parathyroid hormone (1-84) assay as basis for parathyroid hormone monitoring in renal hyperparathyroidism.
    Kaczirek K; Prager G; Riss P; Wunderer G; Asari R; Scheuba C; Bieglmayer C; Niederle B
    Arch Surg; 2006 Feb; 141(2):129-34; discussion 134. PubMed ID: 16490888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Elecsys PTH(1-84) assay with four contemporary second generation intact PTH assays and association with other biomarkers in chronic kidney disease patients.
    Tan K; Ong L; Sethi SK; Saw S
    Clin Biochem; 2013 Jun; 46(9):781-6. PubMed ID: 23384535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.